Reducing Medicare Payments for Urinary Catheters

Published in Billing, Reimbursement, Audits and Compliance on September 19, 2022

From the desk of....

The Office of Evaluation and Inspection, a component of OIG (Office of Inspector General) and HHS (Health and Human Services), recently released "Reducing Medicare’s Payment Rates for Intermittent Urinary Catheters Can Save the Program and Beneficiaries Millions of Dollars Each Year,” a study that was performed on urinary catheters. The study included a sample of 600 traditional Medicare FFS (Fee for Service) claims from the fiscal year 2020 with three HCPCS codes: A4351, A4352, and A4353.  

Many suppliers received letters requesting information from this study. The suppliers that received requests were to submit acquisition costs for catheters, features of the catheters, and whether the catheters were delivered by mail. Comparison of the suppliers’ acquisition costs to Medicare payment amounts was the study's primary purpose.  

The report calculations estimated that traditional Medicare FFS payments were 3.4 times the suppliers’ acquisition costs resulting in $407 million paid by Medicare, whereas suppliers paid approximately $121 million in acquisition costs. The report stated the following: “Recognizing suppliers face other costs beyond the cost of acquiring catheters and need an opportunity to maintain a profit. However, the differences between Medicare reimbursements and suppliers' acquisition costs indicate that Medicare and its beneficiaries can achieve substantial savings while allowing for other costs.”  

PDF Chart

The recommendation from the OIG to CMS was to reduce the Medicare FFS payment rates for intermittent urinary catheters, and in doing so, CMS should continue to take steps to ensure beneficiaries have access to the catheters that best serve their medical needs. 

Previously, when CMS sought to obtain savings for other items under federal statutes and regulations, the agency had used competitive bidding for its “inherent reasonableness” process methodologies. CMS suggests both methodologies include mechanisms to consider the protection of beneficiary access.  

The report noted the addition of urinary catheters to the competitive bid program could attain savings dependent upon the bids that suppliers submit to Medicare  

According to the report, if the inherent reasonableness process methodology were chosen, it would allow Medicare to directly modify the payment for these items. Under this methodology, for a payment amount to be considered grossly deficient or excessive, CMS must determine that an adjustment of 15 percent or more is necessary to produce a realistic and equitable payment.  

Furthermore, statutes and regulations do not require CMS to implement the total necessary adjustment at one time. For example, if a reduction of 20 percent were required to produce a realistic and equitable payment amount, CMS could implement the reduction over two years. CMS has used the inherent reasonable process to adjust payment amounts only once (in 1995) to lower payment rates for standard home blood glucose monitors. Before adopting a new payment limit, CMS must take public comment during rulemaking which allows stakeholders to raise concerns about beneficiary access. 

CMS did not explicitly indicate where it concurred with the recommendation. Instead, CMS stated that it will take the recommendations under consideration as it determines appropriate next steps. 

VGM will continue to monitor this issue and report/update information to our members. 

READ THE FULL REPORT HERE


TAGS

  1. billing & reimbursement
  2. medicare
  3. vgm
  4. vgm government

From Our Experts

An Open Discussion About Opportunities in the Diabetic Market, CGM Audits, and Reimbursements thumbnail An Open Discussion About Opportunities in the Diabetic Market, CGM Audits, and Reimbursements In this episode of Industry Matters, we talk with president of The van Halem Group, Wayne van Halem, and sales manager for GEMCO, Joseph Ault, about CGM audits, qualifications for reimbursement and documentation, as well as the opportunities in the diabetic market. Featured Service: The van Halem Group thumbnail Featured Service: The van Halem Group There's been a lot of questions and confusion surrounding telehealth services and how they relate to DMEPOS claims. This article by Wayne van Halem, originally featured in “VGM Playbook: Technology and the Patient Care Continuum Guide to Remote Work,” addresses whether or not telehealth services can be used to qualify a patient for an item of DMEPOS during the PHE. Return of the Audits thumbnail Return of the Audits HME Business recently wrote about the news that CMS planned to resume audits by Aug. 3 and that it took many by surprise. Then CMS said it would resume audits in a phased approach. What are the details and what can providers expect? CMS Audits Resume August 3, 2020 thumbnail CMS Audits Resume August 3, 2020 In this episode, we chat with Wayne van Halem and Kelly Grahovac of The van Halem Group about the CMS audits returning today, August 3, and what DMEPOS providers need to know. Member Q&A From The van Halem Group: New Order Requirement and Member Q&A From The van Halem Group: New Order Requirement and "Master List" I'm curious about this new order requirement. I see that Medicare updated the notice on 2/12/20, and I'm curious about the “Master List” of items that still needs a WOPD. I'm wondering if PAP equipment and supplies fall under the SWO or the WOPD. Can you help me understand? The Cost of Compliance – An Impassioned Plea to be Proactive thumbnail The Cost of Compliance – An Impassioned Plea to be Proactive Last year, The van Halem Group was engaged by several DME providers that were subject to a 6-year OIG lookback audit. Sadly, for companies that did not have a process in place for proactive chart audits, the 6-year look back resulted in a very expensive lesson. Lookback audits are here to stay, and it's never been more important for providers to have a comprehensive proactive compliance program, and this is one way that The van Halem Group can assist members. OIG to Review PMD Repairs and PAP Supplies thumbnail OIG to Review PMD Repairs and PAP Supplies The Office of Inspector General (OIG) has updated its work plan to include new reviews for PAP replacement supplies and power mobility device repairs. In a recent article from HME News, Medicare paid approximately $945.8 million for replacement supplies in 2017 and 2018, but OIG has previously found that most claims did not comply with Medicare requirements and that DME suppliers often did not have the documentation required to support the need for replacement supplies. Are Inhalation Drugs the Next OIG Six Year Lookback Audit? thumbnail Are Inhalation Drugs the Next OIG Six Year Lookback Audit? Since 2010, the CMS's Comprehensive Error Rate Testing (CERT) program has identified nebulizers and related drugs (i.e., inhalation drugs) among the top 20 supplies with the highest improper Medicare payments. Based on prior reviews, the Office of Inspector General (OIG) conducted a nationwide review to determine if the suppliers included in the review complied with Medicare requirements when billing for inhalation drugs.